Additional Reduction in Serum Phosphorus Levels by Pulverized Lanthanum Carbonate Chewable in Hemodialysis Patients

被引:3
作者
Yamashita, Tetsuri [1 ]
Ogawa, Tetsuya [2 ]
Takahashi, Masaki [1 ]
Mitsuhashi, Tetsuya [2 ]
Shizuku, Junichi [3 ]
Takahashi, Naoshi [3 ]
Ohba, Takashi [3 ]
Miyajima, Sayako [3 ]
Kabaya, Takashi [3 ]
Otsuka, Kuniaki [2 ]
Nitta, Kosaku [1 ]
机构
[1] Tokyo Womens Med Univ, Kidney Ctr, Dept Med, Tokyo 1168567, Japan
[2] Tokyo Womens Med Univ, Med Ctr East, Dept Internal Med, Tokyo 1168567, Japan
[3] Minamisenju Hosp, Tokyo, Japan
关键词
Abdominal X-ray; Hemodialysis; Hyperphosphatemia; Lanthanum carbonate; Phosphate binder; CHRONIC-RENAL-FAILURE; DIALYSIS PATIENT; DOUBLE-BLIND; PHOSPHATE; EFFICACY; CALCIUM; TOLERABILITY;
D O I
10.1111/1744-9987.12036
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Lanthanum carbonate (LC) is one of the relatively new phosphate binders. The general LC dosage form is a chewable pharmaceutical preparation. This investigation was targeted to subjects who do not chew LC chewable preparations adequately, for the purpose of studying the clinical efficacy of changing to pulverized prescriptions, such as changes in serum phosphorus levels (P levels). The study took place at Minamisenju Hospital in October 2011, with 41 subjects on maintenance hemodialysis. We pulverized all of the LC chewable medicines of the LC insufficient mastication group (non-chewing: NC group, n=18) using a crusher, and changed them to pulverized prescriptions. The testing period was set at 10 weeks. In the NC group, there was a significant lowering of P levels from 5.86 +/- 1.31mg/dL before pulverization of the LC chewable preparation (week 0) to 5.38 +/- 1.26mg/dL after 2 weeks of administration of the pulverized medication (P=0.0310), 5.20 +/- 1.25mg/dL after 4 weeks (P=0.0077), and 5.12 +/- 1.34mg/dL after 6 weeks (P=0.0167). P levels in other patients than NC group showed no significant change. In this study, the P levels in the NC group was lowered significantly by changing the LC chewable to the pulverized prescription, and the residual LC images on the abdominal X-rays disappeared to the point where they could barely be confirmed.
引用
收藏
页码:54 / 59
页数:6
相关论文
共 21 条
[1]   Hyperphosphataemia in renal failure - Causes, consequences and current management [J].
Albaaj, F ;
Hutchison, AJ .
DRUGS, 2003, 63 (06) :577-596
[2]   Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate [J].
Behets, GJ ;
Verberckmoes, SC ;
Oste, L ;
Bervoets, AR ;
Salomé, M ;
Cox, AG ;
Denton, J ;
De Broe, ME ;
D'Haese, PC .
KIDNEY INTERNATIONAL, 2005, 67 (05) :1830-1836
[3]   Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[4]   A peritoneal dialysis patient with an unusual abdominal Film [J].
Chuang, C-L ;
Chiou, S-Y ;
Li, S-Y ;
Jian, D-Y ;
Chen, J-Y .
KIDNEY INTERNATIONAL, 2007, 72 (10) :1291-1292
[5]  
Fukagawa M, 2013, THER APHER IN PRESS, V17
[6]   Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis [J].
Goodman, WG ;
Goldin, J ;
Kuizon, BD ;
Yoon, C ;
Gales, B ;
Sider, D ;
Wang, Y ;
Chung, J ;
Emerick, A ;
Greaser, L ;
Elashoff, RM ;
Salusky, IB .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (20) :1478-1483
[7]   Lanthanum carbonate [J].
Harrison, TS ;
Scott, LJ .
DRUGS, 2004, 64 (09) :985-996
[8]   Phosphate-binding efficacy of crushed vs. chewed lanthanum carbonate in hemodialysis patients [J].
How, Priscilla P. ;
Anattiwong, Prathana ;
Mason, Darius L. ;
Arruda, Jose A. ;
Lau, Alan H. .
HEMODIALYSIS INTERNATIONAL, 2011, 15 (01) :95-99
[9]   Long-term efficacy and safety profile of lanthanum carbonate: Results for up to 6 years of treatment [J].
Hutchison, Alastair J. ;
Barnett, M. Edwina ;
Krause, Rolfdieter ;
Kwan, Jonathan T. C. ;
Siami, Ghodrat A. .
NEPHRON CLINICAL PRACTICE, 2008, 110 (01) :C15-C23
[10]   Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia [J].
Joy, MS ;
Finn, WF .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 42 (01) :96-107